This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Singer M, Deutschman CS, Seymour CW, et al The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10.SingerMDeutschmanCSSeymourCWet alThe Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA20163158011010.1001/jama.2016.0287496857426903338Search in Google Scholar
Kaukonen K, Bailey M, Suzuki S, et al Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308-16.KaukonenKBaileyMSuzukiSet alMortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012JAMA201431113081610.1001/jama.2014.263724638143Search in Google Scholar
Bone RC, Balk RA, Cerra FB, et al American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.BoneRCBalkRACerraFBet alAmerican College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsisCrit Care Med1992208647410.1097/00003246-199206000-00025Search in Google Scholar
Ventetuolo CE, Levy MM. Sepsis: a clinical update. Clin J Am Soc Nephrol. 2008;3:571-7.VentetuoloCELevyMMSepsis: a clinical updateClin J Am Soc Nephrol20083571710.2215/CJN.01370307663107817989202Search in Google Scholar
Venkata C, Kashyap R, Farmer JC, et al Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1:9.VenkataCKashyapRFarmerJCet alThrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcomeJ Intensive Care20131910.1186/2052-0492-1-9437302825810916Search in Google Scholar
Daly ME. Determinants of platelet count in humans. Haematol. 2011;96:10-3.DalyMEDeterminants of platelet count in humansHaematol20119610310.3324/haematol.2010.035287301275821193429Search in Google Scholar
Drews RE, Weinberger SE. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med. 2000;162:347–51.DrewsREWeinbergerSEThrombocytopenic disorders in critically ill patientsAm J Respir Crit Care Med20001623475110.1164/ajrccm.162.2.ncc3-0010934051Search in Google Scholar
Stephan F, Hollande J, Richard O, et al Thrombocytopenia in a surgical ICU. Chest. 1999;115:1363–70.StephanFHollandeJRichardOet alThrombocytopenia in a surgical ICUChest199911513637010.1378/chest.115.5.136310334154Search in Google Scholar
Bonfiglio MF, Traeger SM, Kier KL, et al Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother. 1995;29:835–42.BonfiglioMFTraegerSMKierKLet alThrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patientsAnn Pharmacother1995298354210.1177/1060028095029009018547728Search in Google Scholar
Cawley MJ, Witbrodt ET, Boyce EG, et al Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19:108–13.CawleyMJWitbrodtETBoyceEGet alPotential risk factors associated with thrombocytopenia in a surgical intensive care unitPharmacotherapy1999191081310.1592/phco.19.1.108.305189917084Search in Google Scholar
Shalansky SJ, Verma AK, Levine M, et al Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy. 2002;22:803–13.ShalanskySJVermaAKLevineMet alRisk markers for thrombocytopenia in critically ill patients: a prospective analysisPharmacotherapy2002228031310.1592/phco.22.11.803.33634Search in Google Scholar
Abraham E, Anzueto A, Gutierrez G, et al Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet. 1998;351:929–33.AbrahamEAnzuetoAGutierrezGet alDouble-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study groupLancet19983519293310.1016/S0140-6736(05)60602-2Search in Google Scholar
Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International sepsis trial study group. Crit Care Med. 1996;24:1431–40.CohenJCarletJINTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International sepsis trial study groupCrit Care Med19962414314010.1097/00003246-199609000-000028797612Search in Google Scholar
Munford RS, Sufredini AF. Sepsis, Severe sepsis, and septic shock. In Mandell GL, Bennet JE, Dolin R. (Eds.) Mandell, Douglas, and Bennet’s Principles and Practice of Infectious Diseases. Seventh Edition. Philadelphia: Churchill Livingstone. 2010, pp. 987-1010.MunfordRSSufrediniAFSepsis, Severe sepsis, and septic shockInMandellGLBennetJEDolinREdsMandell, Douglas, and Bennet’s Principles and Practice of Infectious Diseases. Seventh EditionPhiladelphiaChurchill Livingstone2010pp987101010.1016/B978-0-443-06839-3.00070-9Search in Google Scholar
Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129:2829–35.LambertMPGernsheimerTBClinical updates in adult immune thrombocytopeniaBlood201712928293510.1182/blood-2017-03-754119581373628416506Search in Google Scholar
Gonzalez-Porras JR, Bastida JM. Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Ther Adv Drug Saf. 2018;9:263–85.Gonzalez-PorrasJRBastidaJMEltrombopag in immune thrombocytopenia: efficacy review and update on drug safetyTher Adv Drug Saf201892638510.1177/2042098618769587597140129854389Search in Google Scholar
Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018;2:454–61.KimTODespotovicJLambertMPEltrombopag for use in children with immune thrombocytopeniaBlood Adv201824546110.1182/bloodadvances.2017010660585847329487060Search in Google Scholar
Bussel JB, Cheng G, Saleh MN, et al Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-47.BusselJBChengGSalehMNet alEltrombopag for the treatment of chronic idiopathic thrombocytopenic purpuraN Engl J Med200735722374710.1056/NEJMoa07327518046028Search in Google Scholar
Barrios NJ, Humbert JR, McNeil J. Treatment of acute idiopathic thrombocytopenic purpura with high-dose methylprednisolone and immunoglobulin. Acta Haematol. 1993;89:6-9.BarriosNJHumbertJRMcNeilJTreatment of acute idiopathic thrombocytopenic purpura with high-dose methylprednisolone and immunoglobulinActa Haematol1993896910.1159/0002044748480491Search in Google Scholar
Cheng G. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. 2012;3:155-64.ChengGEltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profileTher Adv Hematol201231556410.1177/2040620712442525357343923556122Search in Google Scholar
Saleh MN, Bussel JB, Cheng G, et al Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121:537–45.SalehMNBusselJBChengGet alSafety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyBlood20131215374510.1182/blood-2012-04-425512Search in Google Scholar
McMillan R, Wang L, Tomer A, et al Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.McMillanRWangLTomerAet alSuppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITPBlood20041031364910.1182/blood-2003-08-2672Search in Google Scholar
Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009;373:1562–69.NurdenATViallardJFNurdenPNew-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpuraLancet200937315626910.1016/S0140-6736(09)60255-5Search in Google Scholar
Ali N, Auerbach HE. New-onset acute thrombocytopenia in hospitalized patients: pathophysiology and diagnostic approach. J Community Hosp Intern Med Perspect. 2017;7:157–67.AliNAuerbachHENew-onset acute thrombocytopenia in hospitalized patients: pathophysiology and diagnostic approachJ Community Hosp Intern Med Perspect201771576710.1080/20009666.2017.1335156553821628808508Search in Google Scholar
Kaushansky K. Thrombopoiesis. Semin Hematol. 2015;52:4– 11.KaushanskyKThrombopoiesisSemin Hematol20155241110.1053/j.seminhematol.2014.10.00325578413Search in Google Scholar
Mason KD, Carpinelli MR, Fletcher JI, et al Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173–86.MasonKDCarpinelliMRFletcherJIet alProgrammed anuclear cell death delimits platelet life spanCell200712811738610.1016/j.cell.2007.01.03717382885Search in Google Scholar
Akca S, Haji-Michael P, de Mendonça A, et al Time course of platelet counts in critically ill patients. Crit Care Med. 2002;30:753–6.AkcaSHaji-MichaelPde MendonçaAet alTime course of platelet counts in critically ill patientsCrit Care Med200230753610.1097/00003246-200204000-0000511940740Search in Google Scholar
Cawley MJ, Witbrodt ET, Boyce EG, et al Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19:108–13.CawleyMJWitbrodtETBoyceEGet alPotential risk factors associated with thrombocytopenia in a surgical intensive care unitPharmacotherapy1999191081310.1592/phco.19.1.108.305189917084Search in Google Scholar
Shalansky SJ, Verma AK, Levine M, et al Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy. 2002;22:803–13.ShalanskySJVermaAKLevineMet alRisk markers for thrombocytopenia in critically ill patients: a prospective analysisPharmacotherapy2002228031310.1592/phco.22.11.803.3363412126213Search in Google Scholar
Sharma B, Sharma M, Majumder M, et al Thrombocytopenia in septic shock patients–a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007;35:874–80.SharmaBSharmaMMajumderMet alThrombocytopenia in septic shock patients–a prospective observational study of incidence, risk factors and correlation with clinical outcomeAnaesth Intensive Care2007358748010.1177/0310057X070350060418084977Search in Google Scholar
Dewite A, Lepreux S, Villeneuve J, et al Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? Ann. Intensive Care. 2017;7:115.DewiteALepreuxSVilleneuveJet alBlood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? AnnIntensive Care2017711510.1186/s13613-017-0337-7570927129192366Search in Google Scholar
Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Investig. 2003;112:460–7.RiedemannNCGuoRFWardPAThe enigma of sepsisJ Clin Investig2003112460710.1172/JCI200319523Search in Google Scholar
Aziz M, Jacob A, Yang WL, et al Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 2013;93:329–42.AzizMJacobAYangWLet alCurrent trends in inflammatory and immunomodulatory mediators in sepsisJ Leukoc Biol2013933294210.1189/jlb.0912437357902023136259Search in Google Scholar
Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev. 2017;280:41–56.YangDHanZOppenheimJJAlarmins and immunityImmunol Rev2017280415610.1111/imr.12577569951729027222Search in Google Scholar
Xiao W, Mindrinos MN, Seok J, et al A genomic storm in critically injured humans. J Exp Med. 2011;208:2581–90.XiaoWMindrinosMNSeokJet alA genomic storm in critically injured humansJ Exp Med201120825819010.1084/jem.20111354324402922110166Search in Google Scholar
Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105:S13–33.NurdenATPlatelets, inflammation and tissue regenerationThromb Haemost2011105S133310.1160/THS10-11-072021479340Search in Google Scholar
Garraud O, Hamzeh-Cognasse H, Pozzetto B, et al Bench-to-bedside review: platelets and active immune functions-new clues for immunopathology? Crit Care. 2013;17:236.GarraudOHamzeh-CognasseHPozzettoBet alBench-to-bedside review: platelets and active immune functions-new clues for immunopathology?Crit Care20131723610.1186/cc12716405597823998653Search in Google Scholar
Nurden AT. The biology of the platelet with special reference to inflam-mation, wound healing and immunity. Front Biosci (Landmark Ed). 2018;23:726–51.NurdenATThe biology of the platelet with special reference to inflam-mation, wound healing and immunityFront Biosci (Landmark Ed)2018237265110.2741/461328930569Search in Google Scholar
Thiolliere F, Serre-Sapin AF, Reignier J, et al Epidemiology and outcome of thrombocytopenic patients in the intensive care unit: results of a prospective multicenter study. Intensive Care Med. 2013;39:1460–8.ThiolliereFSerre-SapinAFReignierJet alEpidemiology and outcome of thrombocytopenic patients in the intensive care unit: results of a prospective multicenter studyIntensive Care Med2013391460810.1007/s00134-013-2963-323740274Search in Google Scholar
Lim SY, Jeon EJ, Kim HJ, et al The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospital. J Korean Med Sci. 2012;27:1418–23.LimSYJeonEJKimHJet alThe incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospitalJ Korean Med Sci20122714182310.3346/jkms.2012.27.11.1418349268023166427Search in Google Scholar
Antier N, Quenot JP, Doise JM, et al Mecha-nisms and etiologies of thrombocytopenia in the intensive care unit: impact of extensive investigations. Ann Intensive Care. 2014;4:24.AntierNQuenotJPDoiseJMet alMecha-nisms and etiologies of thrombocytopenia in the intensive care unit: impact of extensive investigationsAnn Intensive Care201442410.1186/s13613-014-0024-xSearch in Google Scholar
Francois B, Trimoreau F, Vignon P, et al Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103:114–20.FrancoisBTrimoreauFVignonPet alThrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factorAm J Med19971031142010.1016/S0002-9343(97)00136-8Search in Google Scholar
Stephan F, Thioliere B, Verdy E, et al Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis. 1997;25:1159–64.StephanFThioliereBVerdyEet alRole of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shockClin Infect Dis19972511596410.1086/5160869402376Search in Google Scholar
Ghosh TK, Khan N, Malik A. Platelet auto-antibodies in septicaemic patients. Indian J Pathol Microbiol. 1999;42:31-5.GhoshTKKhanNMalikAPlatelet auto-antibodies in septicaemic patientsIndian J Pathol Microbiol199942315Search in Google Scholar
Graham SM, Liles WC. Platelets in sepsis: beyond hemostasis. Blood. 2016;127:2947-9.GrahamSMLilesWCPlatelets in sepsis: beyond hemostasisBlood20161272947910.1182/blood-2016-03-70616827313324Search in Google Scholar
Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost. 2014;12:1764-75.HerterJMRossaintJZarbockAPlatelets in inflammation and immunityJ Thromb Haemost20141217647510.1111/jth.1273025224706Search in Google Scholar
Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11:264-74.SempleJWItalianoJE JrFreedmanJPlatelets and the immune continuumNat Rev Immunol2011112647410.1038/nri295621436837Search in Google Scholar
GlaxoSmithKline. Promacta (eltrombopag tablets): US prescribing information. 2011. Available at htp://us.gsk.com/products/assets/us_promacta.pdf [accessed 23 January 2019].GlaxoSmithKline. Promacta (eltrombopag tablets): US prescribing information2011Available athtp://us.gsk.com/products/assets/us_promacta.pdfaccessed 23 January 2019Search in Google Scholar
Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood. 2004;104:59b.ErhardtJErickson-MillerCLTapleyPSB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitroBlood200410459b10.1182/blood.V104.11.3888.3888Search in Google Scholar
